"There are only a handful of people in the world who have experience in running a direct-to-consumer genetic testing company ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

TTAM Research Institute - 23andMe's co-founder and former CEO Anne Wojcicki's new company - is the winner in a final round of ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for ...

A nonprofit led by the co-founder of genetic testing company 23andMe has won a bid to purchase the company, which declared bankruptcy in March.

Oklahoma Attorney General Gentner Drummond and attorneys general from 27 other states sue to block the sale of customer ...

TTAM replaces biotech company Regeneron as 23andMe's buyer. Last month, Regeneron won the bidding during the bankruptcy ...

In today's Pharmalittle roundup, we're reading about a Sarepta setback with its Duchenne drug, the FDA workload causing a delay, and more.

TTAM Research Institute, the nonprofit led by 23andMe's former CEO Anne Wojcicki, has won back 23andMe’s core assets: its Personal Genome Service, Research Services, and telehealth subsidiary Lemonaid ...